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Abstract
Rationale Repeated activation of corticotropin-releasing
factor (CRF) receptors is associated with increased anxiety
and enhanced stress responsivity, which may be mediated
via limbic GABAergic and glutamatergic transmission.
Objective The present study investigated molecular and
functional alterations in GABAA receptor (GABAAR) and
metabotropic glutamate receptor (mGluR) responsivity in
transgenic mice that chronically overexpress CRF.
Methods CRF1 receptor, GABAAR, and mGluR sensitivity
were determined in CRF-overexpressing mice using the
stress-induced hyperthermia (SIH) test. In addition, we
measured mRNA expression levels of GABAAR α subunits
and mGluRs in the amygdala and hypothalamus.
Results CRF-overexpressing mice were less sensitive to the
anxiolytic effects of the CRF1 receptor antagonists
CP154,526 and DMP695, the GABAAR α3-selective
agonist TP003 (0–3 mg/kg) and the mGluR2/3 agonist
LY379268 (0–10 mg/kg) in the SIH test. The hypothermic
effect of the non-selective GABAAR agonist diazepam (0–
4 mg/kg) and the α1-subunit-selective GABAAR agonist
zolpidem (0–10 mg/kg) was reduced in CRF-
overexpressing mice. No genotype differences were found
using the GABAAR α5-subunit preferential compound SH-
053-2′F-R-CH3 and mGluR5 antagonists MPEP and MTEP.
CRF-overexpressing mice showed decreased expression
levels of GABAAR α2 subunit and mGluR3 mRNA levels
in the amygdala, whereas these expression levels were
increased in the hypothalamus. CRF-overexpressing mice
also showed increased hypothalamic mRNA levels of α1
and α5 GABAAR subunits.
Conclusions We found that lifelong CRF overproduction is
associated with altered gene expression and reduced
functional sensitivity of discrete GABAA and mGluR
receptor subtypes. These findings suggest that sustained
over-activation of cerebral CRF receptors may contribute to
the development of altered stress-related behavior via
modulation of GABAergic and glutamatergic transmission.
Keywords SIH.Corticotropin-releasing factor.Anxiety.
Stress.Temperature.Emotional fever.Glutamate.
Benzodiazepine.Mouse
Introduction
The neuropeptide corticotropin-releasing factor (CRF) was
initially characterized as the principal HPA-axis modulator
in response to stress (Vale et al. 1981). However, CRF has
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DOI 10.1007/s00213-011-2423-0been found to orchestrate autonomic, immune, and behav-
ioral stress-related responses via central CRF1 and CRF2
receptors (Heinrichs and Koob 2004). These non-endocrine
CRF brain circuits extend outside the hypothalamus and
include cortical, limbic, striatal, and brainstem areas
(Hauger et al. 2006). In line with a pivotal role in
modulating the stress system, CRF dysfunction appears to
be present in various psychiatric disorders including anxiety
disorders, drug addiction, major depressive disorder, and
schizophrenia (Binder and Nemeroff 2010; Hauger et al.
2009; Kehne and Cain 2010; Logrip et al. 2011; Millan
2003; Reul and Holsboer 2002).
A transgenic mouse model of long-term CRF over-
expression has been proposed to model CRF dysfunction.
In these animals, chronically elevated CRF levels in the
central nervous system are associated with behavioral,
neurochemical, autonomic, and physiological changes,
including altered HPA axis activity, dexamethasone non-
suppression, and reduced heart rate variability (Groenink et
al. 2003). These data suggest that chronic postnatal CRF
overproduction in these mice leads to alterations mimicking
findings that are associated with anxiety disorders and
major depression (Binder and Nemeroff 2010; Licht et al.
2009; Linthorst 2005). Clearly, exogenous CRF adminis-
tration has been found to elicit arousal and anxiety,
putatively through CRF1 receptor stimulation (Bijlsma et
al. 2011; Heinrichs et al. 1997; Kehne and Cain 2010;
Millan 2003). However, other neurotransmitter systems
such as the GABAA and glutamate system may adjust in
response to (sub)chronic CRF receptor activation. In
support, CRF has been shown to increase GABA release
in the amygdala (Bagosi et al. 2008; Kash and Winder
2006; Nie et al. 2004) and striatum (Sirinathsinghji and
Heavens 1989), while also affecting excitatory glutamater-
gic transmission depending on localization (pre/postsynap-
tic) and the CRF receptor type (Liu et al. 2004). Moreover,
repeated central infusion of the CRF receptor agonist
urocortin into the basolateral amygdala (BLA) resulted in
long-lasting deficits in fast GABAA receptor-mediated
inhibitory transmission which could be prevented by
NMDA receptor antagonists (Rainnie et al. 2004). There-
fore, the present study aimed to investigate the putative link
between chronic central CRF overexpression and subse-
quent alterations in GABAA and glutamate receptor
sensitivity. To this end, we used the stress-induced
hyperthermia (SIH) test. This test is based on the fact that
stress-induced increases in body temperature can be
reversed by putative anxiolytics, including (non-)selective
GABAA receptor agonists, metabotropic glutamate receptor
(ant)agonists, and CRF1 receptor antagonists (Bouwknecht
et al. 2007; Vinkers et al. 2008). If chronic CRF release
elicits long-lasting changes in fast neurotransmitter sys-
tems, this would provide a putative mechanism by which
CRF dysfunction could contribute to the emergence of
stress-related disorders.
Materials and methods
Animals
Transgenic mice overexpressing neural CRF were generat-
ed as described previously (Dirks et al. 2002). Briefly, the
CRF transgene was composed of the complete coding
sequence of rat CRF cDNA (.6-kb fragment), which was
inserted into an 8.2-kb genomic DNA fragment encompass-
ing the murine Thy-1.2 gene, including regulatory regions
and polyadenylation signal sequence. The Thy-1 regulatory
sequences drive constitutive transgene expression in post-
natal and adult neurons. Subsequent breeding at the local
breeding facilities (Utrecht, the Netherlands) consisted of
matings between heterozygous transgenic males (C57BL/6J
background) and C57BL/6JIco females (Charles River, the
Netherlands).
Male transgenic CRF-overexpressing mice (15th gener-
ation) were used in these experiments. Littermate WT mice
served as control mice. Animals were group-housed at
constant room temperature (21±2°C) and relative humidity
(50–60%) with PVC tubing as cage enrichment. Standard
rodent food pellets (Special Diet Services, Witham, Essex,
United Kingdom) and water were freely available. Mice
were maintained on a 12-h light–dark cycle (lights on at
6 AM). All experiments were performed in accordance with
the governmental guidelines for care and use of laboratory
animals and approved by the Ethical Committee for Animal
Research of the Faculties of Sciences, Utrecht University,
The Netherlands.
Drugs
Diazepam (base) and zolpidem (tartaric acid salt) were
obtained from Sigma Aldrich. MPEP HCl (2-methyl-6-
(phenylethynyl)pyridine) and MTEP (3-((2-methyl-4-thia-
zolyl)ethynyl)pyridine) were obtained from Alexis Bio-
chemicals. LY379268 (1R,4R,5S,6R)-2-oxa-4-aminobicyclo
[3.1.0]hexane-4,6-dicarboxylate) was obtained from Tocris.
SH-053-2′F-R-CH3 (the (R) stereoisomer of 8-ethynyl-4-
methyl-6-phenyl-4H-2,5,10b-triaza-benzo[e]azulene-3-car-
boxylic acid ethyl ester) was synthesized by the laboratory
of Dr. J.M. Cook (University of Wisconsin-Milwaukee,
USA). TP003 (4,2'-dufluoro-5'-[8-fluoro-7-(1-hydroxy-1,
methylethyl)imidazo[1,2-a]pyridin-3-yl]biphenyl-2-carbon-
itrile) was synthesized according to published methods
(Dias et al. 2005; Humphries et al. 2006). CP154,526 HCl
(butyl-ethyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-
pyrrolo [2.3-d] pyrimidin-4-yl]amine) and DMP695 mesy-
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methyl-(2-methoxyethyl]-6-methyl-1H-1,2,3,triazolo[4,5-c]
pyridin-4-amine) were gifts from Institut de Recherche,
Servier, Croissy/Seine France. An injection volume of
10 ml/kg was used for intraperitoneal injections of all
drugs. All drugs were suspended in gelatine–mannitol
0.5%/5%. Fresh solutions and suspensions were prepared
each testing day.
The stress-induced hyperthermia procedure
The SIH procedure was carried out according to standard
procedures(Groeninketal.2009). Briefly, animals (n=10–13)
were injected intraperitoneally with vehicle or drug 60 min
before the first temperature measurement (T1). The tempera-
ture was again measured 10 min later (T2), representing the
stress-induced body temperature. The stress-induced hyper-
thermia response was calculated by subtracting T1 from T2.A
within-subject design was used, and cages were randomly
and evenly allocated. The body temperature of mice was
measured by rectally inserting a thermistor probe by a length
of 2 cm. Digital temperature recordings were obtained with
an accuracy of 0.1°C using a Keithley 871A digital
thermometer (NiCr–NiAl thermocouple). The probe, dipped
into silicon oil before inserting, was held in the rectum until a
stable rectal temperature had been obtained for 20 s.
Quantitative PCR analysis
GABAA receptor subunit levels as well as mGlu receptor
mRNA levels were determined in drug-naïve wildtype and
transgenic mice. Mice were decapitated, brains were
removed and stored at −80°C until further use. Sections
of 0.5 mm were made using a cryostat and were kept frozen
while the hypothalamus and amygdala were dissected under
a binocular microscope. We chose to study the hypothala-
mus and amygdala for mRNA expression because these
brain areas have been shown to be pivotal in the autonomic
stress responses such as the stress-induced hyperthermia
response (Ulrich-Lai and Herman 2009; Vinkers et al.
2008). Tissue samples were homogenized in Trizol reagent
(Invitrogen, the Netherlands) followed by a clean-up with
NucleoSpin®RNA Clean-upXS(MacheryNagel,Germany).
Reverse transcriptase was performed using the RevertAid™
kit (Fermentas, Germany) and an oligo(dT) primer. The
following protocol was used for all PCR reactions, carried
out in 20-μl reactions in an ABI PRISM 700 (Applied
Biosystems,theNetherlands):15min at95°C,followedby40
cycles consisting of 15 s at 95°C and 60 s at 60°C.
Each reaction mix contained 0.1 μM of each of the
gene specific primers and ABsolute™ QPCR SYBR®
Green mix (Abgene, Epsom, United Kindom). The
efficiency of a given PCR reaction was determined
using five two-fold dilutions of a mixture of the obtained
cDNA samples. Each reaction had an efficiency close to
100%. Measured cDNA levels were normalized against
the levels of GAPDH. The following primers were used
(FP, RP): GAPDH (GCACCCTGCATTATTTTGTCA,
CTTCCAGGAGCGAGACCCCA), GABAA receptor α1
subunit (CCACACCCCATCAATAGGTTCT, AATTCT
CGGTGCAGAGGACTGAA), GABAA receptor α2 sub-
unit (GGGACGGGAAGAGTGTAGTCAA, CCGCATA
GGCGTTGTTCTGT), GABAA receptor α3 subunit (GC
CCACTGAAGTTTGGAAGCTAT, CATCCTGTGCTAC
TTCCACAGATT), GABAA receptor α5 subunit (GCCC
AGAGAGTCTCTGGAGCT,GGGCCACCTCTCCAA
AGTAAAC), mGlur2 receptor (AACCTTGGTCAAGGG
TCTG, AAGCGACGATGTTGTTGAG), mGlur3 receptor
(CCTGGATGGAAAGAAGTTG, TTGAATGGAGCTGT
GAAG), and the mGlur5 receptor(TACTTCTGGGCAGT
GATG, GACAGCTTCTCGCTGATAC).
Data analysis
For SIH experiments, a basal temperature (T1), an end
temperature (T2), and the difference (SIH response=T2−T1)
was determined for each individual mouse. Treatment
effects on the SIH response and basal body temperature
(T1) were evaluated using a repeated-measures analysis of
variance with “drug” as within-subject factor and “geno-
type” as between-subject factor. For post-hoc comparisons,
Dunnett’s t tests were applied. mRNA levels were analyzed
using a univariate analysis of variance with genotype (WT/
CRF-OE) as a fixed factor. A probability level of p<0.05
was set as statistically significant.
Results
CP154,526 (0–40 mg/kg, IP)
CP154,526 affected the SIH response differently in WT
animals compared to CRF-OE mice (CP154,526×
genotype interaction F3,60=3.60, p<0.05) (Fig. 1b).
Separate analysis of the genotypes revealed that
CP154,526 reduced the SIH response in WT animals
(F3,33=8.12, p<0.001) but not in CRF-OE animals (F3,30=
2.59, p=0.11). In WTanimals, post hoc analysis showed that
this effect was attributable to the 10 and 20 mg/kg doses of
CP154,526.
CP154,526 lowered basal body temperature regardless of
genotype (CP154,526 effect F3,60=38.57, p<0.01;
CP154,526×genotype interaction, F3,60=0.54, p=0.66,
NS; genotype effect F1,20=0.66, p=0.43, NS) (Fig. 1a).
Post hoc analysis revealed that this effect was significant
only at the 40 mg/kg dose of CP154,526.
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DMP695 reduced the SIH response to a larger extent in WT
animals compared to CRF-OE mice (DMP695×genotype
interaction F3,63=5.63, p<0.01) (Fig. 1d). Separate analysis
of the genotypes showed that DMP695 reduced the SIH
response in WT animals (F3,30=10.41, p<0.01) as well as
CRF-OE animals (F3,33=6.26, p<0.01). Post hoc analysis
indicated that in WT mice, all DMP695 doses significantly
reduced the SIH response, whereas in CRF-OE animals,
only the highest dose of DMP695 reduced the SIH
response.
DMP695 increased body temperature regardless of
genotype (DMP695 effect F3,63=6.33, p<0.01; DMP695×
genotype interaction, F3,63=1.07, p=0.37, NS) (Fig. 1c).
Post hoc analysis revealed that compared to vehicle, this
increase was significant at the 20 and 40 mg/kg doses of
DMP695.
Diazepam (0–4 mg/kg, IP)
The hypothermic effect of diazepam was dependent on
genotype (diazepam×genotype interaction, F3,63=2.77,
p<0.05) (Fig. 2a). Separate analysis of the genotypes
indicated that diazepam reduced basal body temperature
in WT animals (F3,36=7.77,p<0.001) but not in CRF-OE
animals (F3,27=0.10, p=0.96, NS). In WT animals, post
hoc analysis showed that only the 4 mg/kg dose of
diazepam significantly reduced basal body temperature.
Diazepam reduced the SIH response regardless of
genotype (diazepam effect F3,63=17.25, p<0.001; diaze-
pam×genotype interaction F3,63=0.17, p=0.92, NS; geno-
type effect F1,21=0.03, p=0.86, NS) (Fig. 2b). Post hoc
analysis revealed that diazepam significantly reduced the
SIH response at all doses compared to vehicle.
Zolpidem (0–10 mg/kg, IP)
Zolpidem affected the SIH response regardless of genotype
(zolpidem effect F2,40=5.21, p=0.01; zolpidem×genotype
interaction F2,40=0.52, p=0.60, NS; genotype effect F1,20=
0.17, p=0.69, NS) (Fig. 2d). Post hoc analysis showed that
zolpidem reduced the SIH response only at the 10 mg/kg
dose.
Zolpidem reduced basal body temperature more in WT
animals than in CRF-OE mice (zolpidem×genotype inter-
action, F2,40=6.39, p<0.01) (Fig. 2c). Separate analysis of
the genotypes showed that zolpidem reduced basal body
temperature in WT animals (F2,22=27.86, p<0.001) as well
as in CRF-OE animals (F2,18=21.93, p<0.001). Post hoc
analysis showed that in WTanimals, all zolpidem doses had
a strong hypothermic effect, whereas in CRF-OE animals,
only the 10 mg/kg dose of zolpidem significantly induced
hypothermia.
TP003 (0–3 mg/kg, IP)
TP003 reduced the SIH response, and a trend for a
genotype effect was present (TP003 effect F3,60=5.42,
p<0.01; TP003×genotype interaction F3,60=1.99, p=0.09)
(Fig. 2f). Separate analysis of the genotypes showed that
TP003 reduced the SIH in WTanimals (F3,33=5.16,p<0.01)
Fig. 1 Effects of the CRF1
receptor antagonists CP154,526
(0–40 mg/kg, IP, a–b) and DMP
695 (0–40 mg/kg, IP, c–d)o n
basal body temperature and the
SIH response in wildtype mice
(WT) and CRF-overexpressing
mice (CRF-OE). Asterisk drug
effect relative to vehicle
(*p<0.05; **p<0.01)
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Post hoc analysis indicated that in WT animals, only the
3 mg/kg dose of TP003 significantly reduced the SIH
response.
TP003 reduced basal body temperature regardless of
genotype (TP003 effect F3,60=3.21, p<0.05; TP003×
genotype interaction, F3,60=0.36, p=0.78, NS; genotype
effect F1,20=1.41, p=0.25, NS) (Fig. 2e). After post hoc
analysis, it appeared that this effect was not significant at
any separate TP003 dose.
SH-053-2′F-R-CH3 (0–30 mg/kg, IP)
SH-053-2′F-R-CH3 did not affect the SIH response regardless
of genotype (SH-053-2′F-R-CH3 effect F3,60=2.03, p=0.12,
NS; SH-053-2′F-R-CH3×genotype interaction F3,60=0.67,p=
0.57, NS; genotype effect F1,20=0.36, p=0.56, NS) (Fig. 2h).
SH-053-2′F-R-CH3 did not affect body temperature (SH-
053-2′F-R-CH3 effect F3,60=0.76 p=0.52, NS; SH-053-2′F-
R-CH3×genotype interaction, F3,60=1.20, p=0.32, NS;
genotype effect F1,20=0.08, p=0.78, NS) (Fig. 2g).
Fig. 2 Effects of the non-
subunit selective GABAA
receptor agonist diazepam
(0–4 mg/kg, IP, a–b), the
preferential α1 subunit GABAA
receptor agonist zolpidem
(0–10 mg/kg, IP, c–d), the
GABAA receptor α3 subunit
agonist TP003 (0–3 mg/kg, IP,
e–f) and the GABAA receptor
α5 subunit agonist SH-053-2′F-
R-CH3 (0–30 mg/kg, IP, g–h)o n
basal body temperature and the
stress-induced hyperthermia
(SIH) response in wildtype
(WT) and CRF-overexpressing
mice (CRF-OE). Asterisk drug
effect relative to vehicle
(*p<0.05; **p<0.01;
***p<0.001)
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MPEP reduced the SIH response regardless of genotype
(MPEP effect F3,63=16.55, p<0.001; MPEP×genotype inter-
action F3,63=0.31, p=0.82, NS; genotype effect F1,21=0.95,
p=0.34,NS)(Fig.3b). Post hoc analysis indicated that MPEP
significantly reduced the SIH response at the 10 and
30 mg/kg doses compared to vehicle-treated mice.
MPEP increased body temperature regardless of
genotype (MPEP effect F3,63=5.63, p<0.01; MPEP×
genotype interaction, F3,63=0.65, p=0.58, NS; genotype
effect F1,21=1.66, p=0.21, NS) (Fig. 3a). Post hoc
analysis revealed that this difference was significant at
the 30 mg/kg MPEP dose.
MTEP (0–30 mg/kg, IP)
MTEP reduced the SIH response regardless of genotype
(MTEP×genotypeinteractionF3,63=0.03, p=0.99, NS; MTEP
effect F3,63=21.87, p<0.001; genotype effect F1,21=0.04,
p=0.85, NS) (Fig. 3d). Post hoc analysis showed that
MTEP significantly reduced the SIH response at all doses
compared to vehicle-treated mice.
MTEP overall reduced body temperature regardless of
genotype (MTEP effect F3,63=19.04, p<0.001; MTEP×
genotype interaction, F3,63=0.42, p=0.74, NS; genotype
effect F1,21=0.42, p=0.53, NS) (Fig. 3c). Post hoc analysis
showed that this effect was significant at the 30 mg/kg
MTEP dose (p<0.001).
LY379268 (0–10 mg/kg, IP)
The effect of LY379268 on the SIH response was dependent
on the genotype in which it was tested (LY379268×
genotype interaction F3,60=3.08, p<0.05) (Fig. 3f). Sepa-
rate analysis of the genotypes showed that LY379268
reduced the SIH in WT animals (F3,27=8.85, p<0.001)
but not in CRF-OE animals (F3,27=2.30, p=0.14, NS). Post
hoc analysis indicated that in WT mice, the 3 and 10 mg/kg
LY3792368 doses significantly reduced the SIH response.
Fig. 3 Effects of the mGluR5
antagonists MPEP (0–30 mg/kg,
IP, a–b), MTEP (0–30 mg/kg, IP,
c–d) and the mGluR2/3 agonist
LY379268 (0–10 mg/kg, IP, e-f),
on basal body temperature and
the stress-induced hyperthermia
(SIH) response in wildtype
(WT) and CRF-overexpressing
mice (CRF-OE). Asterisk drug
effect relative to vehicle
(*p<0.05; **p<0.01;
***p<0.001)
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genotype (LY379268 effect F3,60=3.59, p<0.05;
LY379268×genotype interaction, F3,60=0.22, p=0.89, NS;
genotype effect F1,21=0.81, p=0.38, NS) (Fig. 3e). Post
hoc analysis revealed that this effect was significant at the 1
and 10 mg/kg doses of LY379268.
Quantitative PCR analysis
Results of the PCR analysis showed increased GABAAR
α1, α2, α5 subunit, and mGluR3 mRNA levels in the
hypothalamus in CRF-overexpressing group, whereas no
changes were found in α3 subunit, mGluR2, and mGluR5
mRNA levels (Fig. 4a). In contrast, decreased GABAAR α2
subunit and mGluR3 mRNA levels were present in the
amygdala of CRF-overexpressing mice compared to WT
mice (Fig. 4b). All mRNA levels were normalized against
levels of GAPDH.
Discussion
The present studies investigated the putative link between
chronically elevated CRF levels and subsequent alterations
in GABAA and glutamate receptor responsivity using
transgenic mice that overexpress CRF in the brain. To this
end the effect of CRF1 receptor, GABAAR, and mGLuR
ligands were studied in the SIH test. In WT mice, the CRF1
receptor antagonists CP154,526 and DMP695 reduced the
SIH response, which is indicative for an anxiolytic effect of
these compounds (Kehne and Cain 2010; Millan et al.
2001; Zorrilla and Koob 2010). The fact that DMP695
induced a mild hyperthermia of around 0.5°C most
probably did not interfere with the capability to induce a
SIH response because stress-induced rectal temperature is
capable of rising over 39°C, and is even present in
interleukin-induced fever (Vinkers et al. 2009a). Our data
confirm previous anxiolytic effects of the CRF1 receptor
antagonist SSR125543A using the SIH paradigm (Griebel
et al. 2002). In contrast to the effects observed in WT
animals, CRF-OE mice showed an impaired anxiolytic
response to the CRF1 receptor antagonists CP154,526 and
DMP695 (Fig. 1). However, no apparent rightward shift in
responsivity to CRF1 receptor antagonists was found,
suggesting that elevated CRF levels do not induce a
straightforward receptor desensitization or downregulation.
In fact, there is evidence that no prominent CRF receptor
mRNA downregulation is present in CRF-OE mice (Korosi
et al. 2006). Impaired sensitivity to CRF1 receptor
antagonists in CRF-OE mice could also be explained by a
more brain-structure-specific change of CRF receptor
distribution in these mice, with decreased CRF1 receptor
mRNA and increased CRF2 receptor mRNA in specific
brain structures (Korosi et al. 2006). Irreversible and
specific changes in the CRF system in CRF-OE mice seem
to contrast with the fact that prepulse inhibition deficits in
these animals are readily reversed after administration of
CRF1 receptor antagonists (Groenink et al. 2008). However,
a possible caveat is that these PPI deficits—in contrast to
anxiety-related processes—are only present during lasting
activation of CRF receptors (Bijlsma et al. 2011). Here,
CRF1 receptor antagonists either decreased (CP154,526) or
increased basal body temperature (DMP695). We do not
have a good explanation for this difference as both drugs
show high affinity for human (h)CRF1 (Ki, 3.3 nM) and
native rat CRF1 (Ki, 4.6 nM) receptors and low affinity for
CRF2α and other classes of receptors (Millan et al. 2001).
Possible explanations include reduced bioavailability of
CP154-526, or partial agonist activity at and differential
involvement of various CRF1 receptor isoforms and
Fig. 4 mRNA levels of GABAA receptor subunits and mGlur
receptors (mean±SEM) in the hypothalamus a and the amygdala b
of wildtype (WT) on CRF-overexpressing mice (CRF-OE) mice. The
mRNA expression was normalized against GAPDH level. *p<0.05
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temperature were similar across both genotypes, and basal
body temperature was comparable between WT and CRF-
OE mice, suggesting that the role of CRF1 receptors in
stress-induced hyperthermia is different from that in basal
thermoregulatory processes. Acute central CRF administra-
tion increases basal body temperature, suggesting that the
CRF system may directly affect thermoregulatory processes
(Heinrichs et al. 2001). Although Dirks and colleagues
reported increased body temperature in CRF-OE mice in
the late afternoon (maximum 0.5°C) in CRF-OE mice
(Dirks et al. 2002), we found no overall effects of genotype
on basal body temperature. This is probably due to the fact
that the present experiments were carried out between 9 AM
and 2 PM, whereas body temperature in CRF-OE mice was
only found to be moderately increased from 2–5P M .
Chronic CRF overproduction not only resulted in
reduced sensitivity to the anxiolytic effects of CRF1
receptor antagonists, but also in reduced sensitivity to the
anxiolytic effects of the GABAAR α2/3 subunit-selective
agonist TP003 (Dias et al. 2005) and the mGlu2/3R agonist
LY379268. Both TP003 and LY379268 reduced the SIH
response to a lesser extent in CRF-OE animals than in WT
mice but did not result in hypothermia. The SIH-reducing
effect of these compounds is in line with known anxiolytic
effects of both α2/3 selective GABAergic modulators
(Atack 2010; Dias et al. 2005; Mirza et al. 2008) and
mGluR (ant)agonists (Niswender and Conn 2010). We also
report that the hypothermic effect of the non-selective
GABAAR agonist diazepam and the α1-selective GABAAR
agonist zolpidem (Petroski et al. 2006) were less pro-
nounced in CRF-OE than in WT mice (Fig. 2). The
impaired GABAergic and glutamatergic sensitivity in
CRF-OE mice appeared to be specific, as genotype did
not affect responsivity to the α5-subunit preferential
GABAA receptor agonist SH-053-2′F-R-CH3 (Fig. 2)o r
the mGluR5 antagonists MPEP and MTEP (Fig. 3). In
contrast to our results, previous studies did not show a
significant increase of basal body temperature after admin-
istration of MPEP up to oral doses of 30 mg/kg in mice
(Nordquist et al. 2007; Spooren et al. 2002; Spooren et al.
2000). However, the MPEP-induced hyperthermia is minor
with a maximum MPEP-induced hyperthermia of around
0.3°C occurring at the highest dose. In support, MPEP-
induced basal body temperature as reported by Spooren and
colleagues display an apparent trend for body temperature
increases although this does not reach statistical signifi-
cance (Spooren et al. 2000). In support, we administered
MPEP intraperitoneally (compared to oral administration in
the other studies), leading to increased CNS drug levels.
Moreover, the present study used a within-subject
design which may be more sensitive to result in
statistical significance.
Our results confirm and extend the SIH-reducing effects
of (non-)selective GABAergic modulators diazepam, zolpi-
dem, and TP003 (for review, see (Vinkers et al. 2010b)) as
well as those of the glutamatergic compounds (mGluR2/3
agonists and mGluR5 antagonists) (Nordquist et al. 2007;
Spooren et al. 2002). The fact that the α5-subunit
preferential GABAA receptor agonist SH-053-2′F-R-CH3
did not affect basal body temperature nor the SIH response
compared to vehicle-treated mice may suggest that the α5
subunit is not involved in the anxiolytic and hypothermic
effects of benzodiazepines, which is in line with the already
published findings (Atack 2011; Rudolph and Mohler 2006;
Savic et al. 2010). However, the use of α5-selective (silent)
antagonists is warranted to further characterize the role of
this subunit in hypothermia and anxiolysis.
Long-lasting CRF hyperactivity is thus associated with a
decreased GABAergic and glutamatergic receptor sensitiv-
ity at adult age. In our results, either the SIH response
(TP003 and LY379268) or basal body temperature (diaze-
pam and zolpidem) were affected in CRF-OE mice,
suggesting that neurocircuitry involved in these processes
may have adapted in these transgenic mice. These results
may indicate that a blunted SIH attenuation without
concomitant basal body temperature differences reflect
specific dysfunction involving stress-related circuitry in
CRF-OE animals. In support, basal body temperature and
the autonomic stress response have been found to be
regulated independently with a putative role for the
GABAAR α1 subunit in basal thermoregulation and a role
for α2 and α3 subunits in the SIH response (Vinkers et al.
2009b). Our current results are in the line with such a
distinction in α subunit function in the SIH paradigm.
Besides alterations in functional receptor sensitivity,
CRF-OE mice display molecular alterations in GABAAR
and mGluR circuitry in the amygdala and hypothalamus.
These brain areas were chosen since they have been shown
to be pivotal in autonomic stress responsivity (Ulrich-Lai
and Herman 2009; Vinkers et al. 2010a; Vinkers et al.
2008). Also, central thermoregulation is eventually regulat-
ed in the hypothalamus, and a connection between the
anxiety-involved limbic system and the hypothalamic
temperature execution areas is generally assumed (Dimicco
and Zaretsky 2007). Amygdaloid GABAAR α2 subunit and
mGluR3 mRNA levels were decreased in CRF-OE mice
(Fig. 4), whereas opposing effects were found in the
hypothalamus. The hypothalamic increase in α5 subunit
expression may reflect a compensatory mechanism in
which changes in α5-dependent GABAergic transmission
would lead to increased tonic (extra)synaptic activity
(Caraiscos et al. 2004). In support, chronic administration
of anabolic androgenic steroids which can affect mood and
induce anxiety also resulted in increased mRNA expression
of the α5 subunit in the hypothalamus, (Penatti et al. 2009).
904 Psychopharmacology (2012) 219:897–908Moreover, chronic stress led to up-regulation of the α5
subunit expression in the hypothalamic paraventricular
nucleus (Verkuyl et al. 2004). Surprisingly, the impaired
sensitivity to the GABAAR α3 subunit-selective agonist
TP003 was not accompanied by changes in α3 subunit
mRNA expression. This may be due to the fact that α3
subunit expression is relatively low in the amygdala and
hypothalamus. The expression of the α3 subunit is highest
in the cortex, hippocampus, thalamus, and brainstem
(including monoaminergic neurons such as the raphe nuclei
and the locus coeruleus) (Mohler et al. 2002). Also, the α3-
selective nature of TP003 can be questioned. Although
TP003 appears to possess somewhat lower in vitro efficacy
for the α2 subunit compared to the α3 subunit (Dias et al.
2005), these differences may not be so pronounced in vivo.
Moreover, subtype selective GABA compounds that distin-
guish between the α2 and the α3 subtype have not been
developed yet (Atack 2010). Together, TP003 may prove to
be functionally α2/3 subtype selective rather than α3
selective. In support of specific changes in α subunits,
mRNA expression of the γ2 subunit was not altered in the
hypothalamus and amygdala of CRF-overexpressing mice
compared to wildtype mice (data not shown). We did not
investigate mRNA expression of other γ subunits because
the γ1 and γ3 subunits characterize a small population of
GABAA receptors with a reduced affinity for classical
benzodiazepines (McKernan and Whiting 1996).
The fact that CRF-OE mice display more subtle region-
specific differences in CRF1 and CRF2 receptor mRNA
expression suggest that adaptations in the GABAA and
glutamate receptor systems are probably not directly related
to concomitant changes in CRF receptor expression (Korosi
et al. 2006). The finding that chronic CRF exposure exerts
opposing effects on hypothalamic and amygdaloid
GABAAR and mGluR3 mRNA levels may be the related
to the differential effects of CRF1 and CRF2 receptors on
the fast neurotransmitter systems. In support, CRF1 receptor
activation in the amygdala decreased glutamate transmis-
sion, whereas CRF2 receptor activation opposed these
CRF1 receptor-mediated effects on glutamate transmission
(Liu et al. 2004). However, the applied methodology has
important limitations. We cannot exclude the possibility that
changes in the GABA and glutamate system are present in
other brain regions of CRF-overexpressing mice such as the
prefrontal cortex or the hippocampus. Also, no mRNA
expression of amygdaloid and hypothalamic subnuclei was
determined since punching out separate nuclei of these
brain areas is technically very challenging in mice, and
RNA isolation from extremely small tissue samples may
suffer from the low input. Thus, our results do not pinpoint
the exact subnuclei within the hypothalamus or amygdala
that represent the overall changed gene expression. How-
ever, the observed changes are strong indications for
changes in these areas that should be further explored
using other methods such as immunohisochemistry or in
situ hybridisation.
A number of studies support the notion that a disruption
of the balance between glutamatergic excitation and
GABAergic inhibition could underlie CRF-induced
anxiety-like behavior. Repeated administration of urocortin,
a CRF-related ligand into the basolateral amygdala induced
long-lasting anxiety-like responses that were dependent on
NMDA receptor activation but resulted in concomitant
specific loss of GABAA receptor-mediated inhibition
(Rainnie et al. 2004). Also, CRF enhanced GABAAR
inhibitory postsynaptic currents IPSCs in central amygdala
neurons from wild-type and CRF2 receptor knockout mice
but not CRF1 receptor knockout mice (Nie et al. 2004). In
that study, CRF1 but not CRF2 receptor antagonists blocked
these effects in wild type mice, a finding that was later
confirmed using in vitro techniques (Bagosi et al. 2008).
CRF enhanced GABAA-mediated transmission via post-
synaptic activation of CRF1 receptors in the bed nucleus of
the stria terminalis (Kash and Winder 2006), and CRF has
been shown to increase GABA release in the striatum
(Sirinathsinghji and Heavens 1989). In serotonergic dorsal
raphe neurons, CRF elevated presynaptic GABA release
and increased GABAA receptor-mediated miniature IPSCs
that were mediated by both CRF1 and CRF2 receptors
(Kirby et al. 2008). In addition to CRF effects on the
GABAA neurotransmission, Liu et al. (2004) showed
concentration-dependent and opposing effects of CRF on
fast excitatory glutamatergic transmission in the central
nucleus of the amygdala and the lateral septum mediolateral
nucleus. Moreover, CRF potentiated NMDA receptor-
mediated excitation in the ventral tegmental area which
was mediated by CRF2 receptors (Ungless et al. 2003).
Although we found changes in mRNA expression levels
that may suggest alterations at the receptor level associated
with CRF overexpression, we cannot exclude the possibil-
ity that changes in GABAergic and glutamatergic neuro-
transmitter systems in CRF-OE mice may be the result of
changes in intracellular signaling pathways. In support,
CRF is implicated in protein kinase C and Ca
2+/calmodu-
lin-dependent kinase II-dependent long-term neuronal po-
tentiation and depression (Blank et al. 2003; Miyata et al.
1999), and CRF increases calcium currents in central
amygdala neurons (Yu and Shinnick-Gallagher 1998). Also,
CRF-induced changes could be mediated through the
serotonergic system (Lukkes et al. 2008; Price et al. 1998;
Tan et al. 2004). To our knowledge, no GABAA receptor
subunit levels have been assessed in transgenic CRF mice
lines or in rodents that have repeatedly been exposed to
CRF or urocortin infusions.
In conclusion, we show that chronic CRF overproduc-
tion is accompanied by reduced functional GABAA and
Psychopharmacology (2012) 219:897–908 905metabotropic glutamate2/3 receptor sensitivity in parallel
with opposing changes in mRNA expression of these
receptors in the amygdala and hypothalamus. These data
provide evidence that CRF exerts a modulatory role on
GABAergic and glutamatergic pathways in at least the
amygdala and hypothalamus. Thus, these observations
contribute to evidence linking an increased central CRF
drive to the emergence of dysfunctional GABAergic and
glutamatergic transmission which could play a role in
stress-related disorders. Specifically, CRF-induced changes
in activity at GABAAR α3 subunits and mGlu2/3 receptors
may be of particular significance. If chronic CRF-induced
changes in GABAergic and glutamatergic transmission
contribute to the development of anxiety, depressed mood,
drug-seeking, psychosis and other stress-related behavioral
changes associated with sustained over-activation of CRF,
ligands targeting specific classes of GABAA subunits and
mGluR receptors may prove beneficial in the management
of these disorders (Atack 2011; Millan 2003; Nicoletti et al.
2010; Yasuhara and Chaki 2011).
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